This bill changes how certain experimental drugs are classified under federal law. Specifically, it says that drugs approved as "breakthrough therapies" by the FDA can be put into Schedule II of the Controlled Substances Act. Schedule II drugs are ones that doctors can prescribe and patients can use legally, but they're recognized as having a high risk of abuse—think of medications like oxycodone or Adderall. The key difference this bill makes is that these breakthrough therapy drugs would be classified with "severe restrictions," meaning there would be strict rules on how they're prescribed, dispensed, and used. In practical terms, this affects pharmaceutical companies developing new drugs for serious conditions, doctors who want to prescribe these medications, and patients who might benefit from them. The bill essentially creates a pathway for promising new drugs to be legally available while still maintaining tight controls to prevent misuse and abuse.

To amend the Controlled Substances Act to define currently accepted medical use with severe restrictions, and for other purposes.

 <p>This bill provides for the classification of drugs or other substances that are part of approved breakthrough therapies as schedule II controlled substances under the Controlled Substances Act. (Schedule II controlled substances are substances that have a high potential for abuse but have a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions.)</p>